Source: Annual Congress 2010 - Pathology of lung cancer
Disease area: Thoracic oncology

Abstract

INTRODUCTION: The study of tumor associated antigens and immunoregulatory molecules in lung cancer, is of great interest regarding the prospects of immunotherapy.
OBJECTIVE: The aim of this study was to investigate the expression of hTERT and IDO, in patients with lung cancer and how this associated with clinicopathological variables and survival.
MATERIALS AND METHODS: Nine human lung cancer cell lines and 28 patients (mean age 63.4±9.7years) with operable NSCLC were enrolled in the study. hTERT expression was determined by semi-quantitative PCR and IDO expression by quantitative real-time PCR.
RESULTS: hTERT expression was detected in 8/9 cell lines, in 21/24 patients‘ tumor samples and in 3/27 autologous non malignant lung tissues (ANMLT). hTERT expression was significantly associated with T-factor (p=0.017), stage (p=0.037) and tumor volume (p=0.001). IDO expression was detected in 3/9 cell lines, in 21/24 patients‘ tumor samples and in 21/25 ANMLT. The expression of IDO in lung cancer cell lines was significantly lower than that of all patients‘ tumor samples (p=0.014) as well as that of the ANMLT (p=0.021). Only in adenocarcinomas the expression of IDO was higher in tumor samples than in ANMLT (p=0.046). Additionally, high IDO expression was associated with poor overall survival (p=0.033). Although co-expression of the two genes was observed in the majority of tumor samples (75%), their expression was not correlated.
CONCLUSION: The expression of hTERT and IDO mRNA may serve as a valuable prognostic factor and as potential target for cancer immunotherapy.

Rating:

Share or cite this content

Citations should be made in the following way:
T. Kerenidi, M. Zamanakou, S. Tsochas, V. Karanikas, A. E. Germenis, K. I. Gourgoulianis (Greece). Transcriptional expression of human telomerase reverse transcriptase (hTERT) and indoleamine 2,3-dioxygenase (IDO) in non-small cell lung cancer. Eur Respir J 2010; 36: Suppl. 54, 3254

Member's Comments

No comment yet.

Related content which might interest you: Inhibition of B7-H4 gene expression by RNA interference (RNAi) in lung cancer A549 cell line Source: Annual Congress 2011 - Progress in pathology of lung cancer Year: 2011 Transcriptional regulation of the human osteopontin promoter in non-small cell lung cancer Source: Annual Congress 2011 - Progress in pathology of lung cancer Year: 2011 Telomerase expression in lung tumors Source: Eur Respir J 2003; 22: Suppl. 45, 198s Year: 2003 Choice of endogenous control for gene expression in nonsmall cell lung cancer Source: Eur Respir J 2005; 26: 1002-1008 Year: 2005 Thymidylate synthase (TS) polymorphism in non-small cell lung cancer (NSCLC) patients Source: Eur Respir J 2004; 24: Suppl. 48, 78s Year: 2004 Polymorphisms in the interleukin-10 gene promoter are associated with susceptibility to non-small cell lung cancer (NSCLC) Source: Eur Respir J 2005; 26: Suppl. 49, 458s Year: 2005 Adenovirus-mediated E2F-1 gene transfer in nonsmall-cell lung cancer induces cell growth arrest and apoptosis Source: Eur Respir J 2002; 20: 703-709 Year: 2002 Targeting gene of insulin-like growth factor type I (IGF-I) on in vitro model of A549 cell line with triple-helix approach. Perspectives of gene therapy in non-small cell lung (NSCLC) cancer Source: Eur Respir J 2006; 28: Suppl. 50, 387s Year: 2006 Expression of Fhit protein in non-small cell lung cancer (NSCLC) and its correlation with Ki-67, a proliferative marker Source: Eur Respir J 2002; 20: Suppl. 38, 230s Year: 2002 Investigation of survivin gene polymorphism in non-small cell lung cancer patients (NSCLC) Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012 Indoleamine 2,3-dioxygenase 1 (IDO1) activity arrests the apoptosis of Mycobacterium tuberculosis (M. tuberculosis)-infected macrophages Source: Virtual Congress 2021 – Immunological and molecular characterisation of tuberculosis disease and infection Year: 2021 Significant correlation between interleukin-10 expression and progression of non-small cell lung cancer through heme oxygenase Source: Eur Respir J 2005; 26: Suppl. 49, 92s Year: 2005 Aberrant methylation of p16 tumour suppresor gene and DAP kinase in nonsmall cell lung carcinomas Source: Eur Respir J 2001; 18: Suppl. 33, 233s Year: 2001 LATE-BREAKING ABSTRACT: Expression of macrophage migration inhibitory factor (MIF) in the serum and lung tissues in patients with non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012 FGFR1 gene aberrations and FGFR1 protein expression in squamous non-small cell lung cancer (Sq-NSCLC). Source: Virtual Congress 2021 – Biology of lung cancer: preclinical and translational research Year: 2021 XAGE-1b and p53: Potential targets for immunotherapy of non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Specific plasmids encoding shRNA molecules directed against growth factor receptors in cell proliferation inhibition and induction phenotype changes relevant to enhancement of anti-tumor immunity. Model of human non-small (NSCLC) and small (SCLC) cell lung cancer lines Source: Annual Congress 2010 - Pathology of lung cancer Year: 2010 MDM2 gene amplification and mdm2 protein expression in NSCLC cells Source: Eur Respir J 2005; 26: Suppl. 49, 91s Year: 2005 Clinical evaluation of the plasma levels of hTERT and EGFR expression as markers for early detection of non-small cell lung cancer Source: Annual Congress 2009 - Basic science and lung cancer Year: 2009 Adenovirus-mediated AP-2α down-regulates MnSOD expression in lung cancer A549 cells and its molecular mechanism Source: Annual Congress 2011 - Progress in pathology of lung cancer Year: 2011